Nuvilex (NASDAQ:PMCB – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, Zacks reports.
Nuvilex Stock Performance
Shares of PMCB stock traded up $0.02 during mid-day trading on Thursday, hitting $0.84. 529,527 shares of the stock were exchanged, compared to its average volume of 889,599. The stock’s fifty day simple moving average is $0.91 and its two-hundred day simple moving average is $0.98. Nuvilex has a 12-month low of $0.63 and a 12-month high of $1.90. The stock has a market capitalization of $5.71 million, a price-to-earnings ratio of -1.56 and a beta of 0.06.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.
About Nuvilex
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
See Also
- Five stocks we like better than Nuvilex
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- How to Use the MarketBeat Dividend Calculator
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- CD Calculator: Certificate of Deposit Calculator
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
